The Chalcogen, X, Is Part Of A -c(=x)x- Group, Wherein The X's Are The Same Or Diverse Chalcogens Patents (Class 549/79)
-
Publication number: 20110152315Abstract: There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type I1 diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.Type: ApplicationFiled: July 23, 2009Publication date: June 23, 2011Inventors: Trond Ulven, Elisabeth Christiansen
-
Publication number: 20110152241Abstract: The present invention relates to novel cyclic amine and cycloalkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: November 22, 2010Publication date: June 23, 2011Applicant: ALLERGAN, INC.Inventors: Phong X. NGUYEN, Todd M. HEIDELBAUGH
-
Patent number: 7964634Abstract: Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.Type: GrantFiled: April 21, 2009Date of Patent: June 21, 2011Assignee: Allergan, Inc.Inventors: Yariv Donde, Jeremiah H. Nguyen, Mark Holoboski, Mari Posner, Robert M. Burk
-
Patent number: 7960378Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, R1, R2, Z, and G are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: March 17, 2009Date of Patent: June 14, 2011Assignee: Allergan, Inc.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner
-
Publication number: 20110130439Abstract: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.Type: ApplicationFiled: February 8, 2011Publication date: June 2, 2011Applicant: ALLERGAN, INC.Inventors: Yariv Donde, Robert M. Burk, Michael E. Garst
-
Publication number: 20110082261Abstract: Facile ways towards the integration of the regioregular poly(3-alkylthiophene)s onto carbon nanotubes, providing multifunctional materials that combine the extraordinary properties of the carbon nanotubes with those of regioregular poly(3-alkylthiophene)s, are presented.Type: ApplicationFiled: November 12, 2010Publication date: April 7, 2011Applicant: ADVENT TECHNOLOGIES, S.A.Inventors: Christos Chochos, Joannis Kallitsis
-
Patent number: 7906552Abstract: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.Type: GrantFiled: August 10, 2004Date of Patent: March 15, 2011Assignee: Allergan, Inc.Inventors: Yariv Donde, Robert M. Burk, Michael E. Garst
-
Publication number: 20110053939Abstract: Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning—X— is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.Type: ApplicationFiled: November 8, 2010Publication date: March 3, 2011Applicant: REVOTAR BIOPHARMACEUTICALS AGInventors: Ewald M. AYDT, Remo Kranich
-
Patent number: 7863319Abstract: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.Type: GrantFiled: January 16, 2007Date of Patent: January 4, 2011Assignee: Allergan, Inc.Inventors: Yariv Donde, Robert M. Burk, Michael E. Garst
-
Publication number: 20100298347Abstract: Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.Type: ApplicationFiled: December 1, 2008Publication date: November 25, 2010Applicant: MERCK FROSST CANADA LTDInventors: Michel Belley, Denis Deschenes, Rejean Fortin, Jean-Francois Fournier, Sebastien Gagne, Yves Gareau, Jacques Yves Gauthier, Lianhai Li, Joel Robichaud, Michel Therien, Geoffrey K. Tranmer, Zhaoyin Wang
-
Publication number: 20100260778Abstract: Small-molecule inhibitors of Botulinum toxin, including BoNTA, BoNTD and BoNTE are provided, as well as methods of using the inhibitors.Type: ApplicationFiled: September 20, 2006Publication date: October 14, 2010Inventors: Yuan-Ping Pang, Charles B. Millard, Jewn Giew Park, Jing Tang, James J. Schmidt
-
Patent number: 7807758Abstract: A method for preparing a defunctionalized alkylenedioxyheterocycle polymer or copolymer involves providing a polycarboxylic acid derivative functionalized alkylenedioxyheterocycle polymer or copolymer and transforming the polymer or copolymer into a defunctionalized alkylenedioxyheterocycle polymer or copolymer which is polyhydroxy, polythiol, polyamino, or polycarboxylic acid functionalized alkylenedioxyheterocycle polymer or copolymer. The monomers, homopolymers and copolymers for use in the method are new compositions of matter. The polymers containing polycarboxylic acid derivative functionalized alkylenedioxyheterocycle units are soluble polymers which are defunctionalized to yield insoluble polyhydroxy, polythiol, polyamino, or polycarboxylic acid functionalized alkylenedioxyheterocycle polymers.Type: GrantFiled: January 25, 2007Date of Patent: October 5, 2010Assignee: University of Florida Research Foundation, Inc.Inventors: John R. Reynolds, Benjamin Dennis Reeves
-
Publication number: 20100240678Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification.Type: ApplicationFiled: March 10, 2010Publication date: September 23, 2010Inventors: Romyr Dominique, Robert Alan Goodnow, JR., Agnieszka Kowalczyk, Qi Qiao, Achyutharao Sidduri, Jefferson Wright Tilley
-
Publication number: 20100222380Abstract: Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN-COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an ?,?-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients.Type: ApplicationFiled: May 10, 2010Publication date: September 2, 2010Applicant: ARIZONA BIOMEDICAL RESEARCH COMMISSIONInventors: Seth D. Rose, Rosemarie F. Hartman
-
Publication number: 20100212547Abstract: The invention relates to an immersion liquid including at least one compound of the general formula I in which R1 and R2 each include at least one ring structure and X denotes: O, S, NR3 with R3 selected from hydrogen or hydrocarbon, wherein Y denotes independently of each other O, S or NR4 with R4 selected from hydrogen or hydrocarbon. In addition, the invention relates to a further immersion liquid, a compound for an immersion liquid and a use of the immersion liquids or of the compound as an immersion oil for a microscope, in particular for a near-field microscope.Type: ApplicationFiled: February 24, 2010Publication date: August 26, 2010Inventor: Hans-Joachim Weippert
-
Publication number: 20100210653Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome proliferator-activated receptors (PPAR), in particular the PPAR? suptype.Type: ApplicationFiled: April 30, 2010Publication date: August 19, 2010Applicant: HIGH POINT PHARMACEUTICALS, LLCInventors: Miroslav Havranek, Per Sauerberg, Ingrid Pettersson
-
Patent number: 7737293Abstract: An amide is formed by reacting an ?-ketoacid or salt thereof in a decarboxylative condensation reaction with an amine or salt thereof comprising a nitrogen covalently bound to an atom selected from oxygen, nitrogen, and sulfur. The amide bond is formed between the ?-carbon of the ketoacid and the nitrogen of the amine. The ?-ketoacid can be formed using a novel sulfur reagent.Type: GrantFiled: November 10, 2008Date of Patent: June 15, 2010Assignee: Regents of the University of CaliforniaInventors: Jeffrey W. Bode, Ryan M. Fox
-
Publication number: 20100039025Abstract: Disclosed herein are novel electrochromic materials. The electrochromic materials produce various colors and have bistability to achieve red-green-blue full colors. Therefore, the electrochromic materials can be used in a variety of electrochromic devices. Also disclosed herein are electrochromic devices fabricated using the electrochromic materials.Type: ApplicationFiled: April 13, 2009Publication date: February 18, 2010Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Seung Uk SON, Ji Min LEE, Chang Ho NOH
-
Publication number: 20100029745Abstract: The present invention relates to compounds derived from substituted 3-phenyl-1-(thien-2-yl)propan-1-ones, pharmaceutical compositions comprising them as well as their therapeutic applications, notably in the field of human and animal health.Type: ApplicationFiled: December 28, 2007Publication date: February 4, 2010Inventor: Jean-Francois Delhomel
-
Publication number: 20090318481Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.Type: ApplicationFiled: August 28, 2009Publication date: December 24, 2009Inventors: Thomas Daniel AICHER, Guillermo S. CORTEZ, Todd Michael GROENDYKE, Albert KHILEVICH, James Allen KNOBELSDORF, Fredrik Pehr MARMSATER, Jeffrey Michael SCHKERYANTZ, Tony Pisal TANG
-
Patent number: 7632846Abstract: Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these compounds.Type: GrantFiled: April 6, 2005Date of Patent: December 15, 2009Assignee: Merck Patent Gesellschaft mit beschrankterInventors: Jean Jacques Zeiller, Hervè Dumas, Valérie Guyard-Dangremont, Isabelle Berard, Francis Contard, Daniel Guerrier, Gèrard Ferrand, Yves Bonhomme
-
Publication number: 20090251046Abstract: Disclosed herein are novel electrochromic materials. The electrochromic materials produce various colors. The electrochromic materials can be used to form red electrochromic layers in a simple manner. Therefore, the electrochromic materials are suitable for use in the fabrication of RGB full-color electrochromic devices. Also disclosed herein are electrochromic devices fabricated using the electrochromic materials.Type: ApplicationFiled: October 29, 2008Publication date: October 8, 2009Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Seung Uk Son, Chang Ho Noh, Ji Min Lee
-
Publication number: 20090240058Abstract: A compound or its salt having the following formula (II) is used as an activator for PPAR ?: in which each of R11 and R13 is a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms and a halogen atom substituent, etc.; R12 is a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms and a halogen atom substituent, etc.; each of R14 and R15 is a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, or an alkyl group having 1 to 8 carbon atoms and a halogen atom substituent; X1 is CH or N; Z1 is an oxygen atom or a sulfur atom; W1 is an oxygen atom or CH2; and q is an integer of 2 to 4.Type: ApplicationFiled: February 28, 2006Publication date: September 24, 2009Inventors: Shogo Sakuma, Tomio Yamakawa, Nobutaka Mochiduki, Seiichiro Masui, Rie Takahashi, Toshitake Hirai
-
Publication number: 20090227603Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification.Type: ApplicationFiled: February 23, 2009Publication date: September 10, 2009Inventors: Romyr Dominique, Robert Alan Goodnow, JR., Agnieszka Kowalczyk, Jianping Lou, Qi Qiao, Achyutharao Siddurl, Jefferson Wright Tilley
-
Patent number: 7582776Abstract: The invention relates to a process for preparing enantiomerically enriched aryl-aminopropanols and to their use and also to intermediates.Type: GrantFiled: May 18, 2006Date of Patent: September 1, 2009Assignee: Lanxess Deutschland GmbHInventors: Markus Eckert, Claus Dreisbach, Boris Bosch, Andreas Stolle
-
Patent number: 7576223Abstract: The present invention provides a sulfonium salt of the formula (Ia) a polymeric compound comprising a structural unit of the formula (Ib) and a chemical amplification type positive resist composition comprising (A) an acid generator comprising at least one compound selected from the group consisting of a sulfonium salt of the formula (Ia), a polymeric compound comprising a structural unit of the formula (Ib), and a sulfonium salt of the formula (Ic); and (B) resin which contains a structural unit having an acid labile group and which itself is insoluble or poorly soluble in an alkali aqueous solution but becomes soluble in an alkali aqueous solution by the action of an acid.Type: GrantFiled: May 29, 2008Date of Patent: August 18, 2009Assignee: Sumitomo Chemical Company, LimitedInventors: Airi Yamada, Yasunori Uetani, Akira Kamabuchi
-
Publication number: 20090176863Abstract: The present invention is directed to compounds represented by the following structural formula, Formula I: and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) X is selected from the group consisting of O, S, S(O)2, N, and a bond; (b) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30: (c) Y is selected from the group consisting of C, O, S, NH and a single bond; and (d) E is C(R3)(R4)A or A.Type: ApplicationFiled: February 11, 2009Publication date: July 9, 2009Inventors: Nathan Bryan Mantlo, Xiaodong Wang, Guoxin Zhu
-
Patent number: 7553970Abstract: The invention relates to a process for preparing enantiomer-enriched 3-heteroaryl-3-hydroxypropanoic acid derivatives and 3-heteroaryl-1-aminopropan-3-ols, and to their use.Type: GrantFiled: September 24, 2003Date of Patent: June 30, 2009Assignee: Lanxess Deutschland GmbHInventors: Frank Berendes, Markus Eckert, Nils Brinkmann, Claus Dreisbach, Ruth Meissner, Rainhard Koch
-
Publication number: 20080269506Abstract: The present invention provides a sulfonium salt of the formula (Ia) a polymeric compound comprising a structural unit of the formula (Ib) and a chemical amplification type positive resist composition comprising (A) an acid generator comprising at least one compound selected from the group consisting of a sulfonium salt of the formula (Ia), a polymeric compound comprising a structural unit of the formula (Ib), and a sulfonium salt of the formula (Ic); and (B) resin which contains a structural unit having an acid labile group and which itself is insoluble or poorly soluble in an alkali aqueous solution but becomes soluble in an alkali aqueous solution by the action of an acid.Type: ApplicationFiled: May 29, 2008Publication date: October 30, 2008Inventors: Airi Yamada, Yasunori Uetani, Akira Kamabuchi
-
Publication number: 20080260669Abstract: A compound of formula (I): wherein R1 and R2 represent, independently, linear or branched C1-4 alkyl, n=0 to 4 and m=0 to 3. Mixtures of these compounds, methods for their preparation, their use as perfume materials for application to a variety of substrates and their use in flavouring and in articles of manufacture is also provided.Type: ApplicationFiled: April 23, 2007Publication date: October 23, 2008Applicant: Flexitral, Inc.Inventor: Luca Turin
-
Publication number: 20080255206Abstract: The present invention relates to the use of one or more retinoid agonists and/or antagonists comprising retinoids with selective Retinoid X Receptor (RXR) agonistic or antagonistic activity alone or in combination with one or more peroxisome proliferator activated receptor (PPAR) ligands for the manufacture of a medicament for the (preferably oral or topical) treatment (this term including prevention/prophylaxis and/or therapy) of one or more manifestations of metabolic syndrome (also known as syndrome X), also called diseases hereinafter, especially from one or more manifestations thereof selected from the group consisting of diabetes type II, obesity, dyslipidemia, hypertension and polyneuropathy, each of which can also be linked with a high risk of cardiovascular diseases. Corresponding methods, the compounds and combinations for use in the treatment of the mentioned diseases and comparable invention embodiments are also described.Type: ApplicationFiled: October 13, 2006Publication date: October 16, 2008Inventor: Werner Bollag
-
Patent number: 7435835Abstract: The invention relates to a process for preparing enantiomerically pure alcohol of the formula 1, which comprises (i) reducing the ketone of the formula 3to the racemic alcohol of the formula 4, (ii) enantioselectively acylating the racemic alcohol of the formula 4 with succinic anhydride in the presence of a lipase to give the succinic semiester of the formula 7, (iii) separating off the succinic semiester of the formula 7 from the unreacted enantiomer of the formula 4, (iv) reacting the enantiomerically pure alcohol of the formula 4 with methylamine to give the enantiomerically pure alcohol of the formula 1.Type: GrantFiled: January 18, 2005Date of Patent: October 14, 2008Assignee: BASF AGInventor: Rainer Stürmer
-
Publication number: 20080249093Abstract: The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.Type: ApplicationFiled: December 13, 2004Publication date: October 9, 2008Applicant: MERCK & CO., INC.Inventors: Vincent J. Colandrea, George A. Doherty, Jeffrey J. Hale, Pei Huo, Irene E. Legiec, Leslie Toth, Petr Vachal, Lin Yan
-
Publication number: 20080242876Abstract: The invention concerns a process for the manufacture of substituted propionic acids comprising providing a substrate of formula (I): And subjecting the substrate to enantioselective hydrogenation under enantioselective hydrogenation conditions in the presence of an enantioselective hydrogenation catalyst comprising a catalyst ligand having a metallocene group with a chiral phosphorus or arsenic substituent to provide in enantiomeric excess a product of formula (II): or its enantiomer or if applicable its diastereomer.Type: ApplicationFiled: January 13, 2006Publication date: October 2, 2008Applicant: Phoenix Chemicals Ltd.Inventors: Peter McCormack, Chen Weiping, Mohammed Karim
-
Publication number: 20080176912Abstract: The invention is directed to compounds of Formula (I) useful as GPR40 agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, insulin resistance, hyperglycemia, obesity, diabetes such as NIDDM, and other disorders related to lipid metabolism, energy homeostasis, and complications thereof, using compounds of the invention are also described.Type: ApplicationFiled: November 13, 2007Publication date: July 24, 2008Inventors: Gee-Hong Kuo, Fengbin Song, Joseph Gunnet, Keith Demarest
-
Publication number: 20080139505Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.Type: ApplicationFiled: November 15, 2005Publication date: June 12, 2008Inventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang, Nicholas Andrew Magnus
-
Publication number: 20070293561Abstract: Disclosed herein are compounds of the formula or salts or bioisosteres thereof. Therapeutic methods, medicaments, and compositions related thereto are also disclosed.Type: ApplicationFiled: June 19, 2007Publication date: December 20, 2007Inventors: David W. Old, Vinh X. Ngo
-
Publication number: 20070259947Abstract: A compound having a structure is disclosed herein. Compositions, medicaments, and therapeutic methods related thereto are also disclosed.Type: ApplicationFiled: May 1, 2007Publication date: November 8, 2007Inventors: Yariv Donde, Jeremiah H. Nguyen
-
Publication number: 20070232813Abstract: The present invention is generally directed to the use of L-proline and certain derivatives thereof to catalyze the asymmetric self-condensation of ?,?-unsaturated aldehydes to form homodimer and heterodimer cyclohexadienals. Reaction conditions are mild and yet amenable to a variety of different substrates yielding molecules with complex scaffolds from simple precursors. This approach allows for diversification and synthesis of this structural class of compounds in sufficient quantity, purity and enantioselectivity for, e.g., biological investigations and use as fluorescent probes, anti-cancer agents, anti-bacterial agents, and/or anti-fungal agents. The present invention is also generally directed to the cyclohexadienals produced.Type: ApplicationFiled: March 28, 2007Publication date: October 4, 2007Inventors: Coran M. H. Watanabe, Bennie John Bench
-
Patent number: 7223746Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an ? bonds, the solid triangle represents a ? bond, the wavy segments represent ? or ? bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3 is heteroaryl or a substituted heteroaryl radical, R1 and R2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) and wherein R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.Type: GrantFiled: October 26, 2004Date of Patent: May 29, 2007Assignee: Allergan, Inc.Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
-
Patent number: 7217295Abstract: The invention relates to the use of a composition comprising at least one conductive polymer in a cosmetically acceptable medium, said polymer being in soluble form in said medium, as, or for the manufacture of, cosmetic products for giving a visual effect to human keratin fibers and more particularly the hair, and also, when said conductive polymer absorbs in the visible region, as, or for the manufacture of, cosmetic products intended to color said fibers. The invention also relates to the corresponding treatment process.Type: GrantFiled: January 31, 2003Date of Patent: May 15, 2007Assignee: L'Oreal S.A.Inventors: Henri Samain, Grégory Plos, Nathalie Mougin
-
Patent number: 7129268Abstract: Novel compounds of the general formula (I), wherein Ar, R1, R2, X1, X2, Y1, Y, and Z are as defined in the specification, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? subtype.Type: GrantFiled: October 24, 2003Date of Patent: October 31, 2006Assignee: Novo Nordisk A/SInventors: Lone Jeppesen, John Patrick Mogensen, Ingrid Pettersson, Per Sauerberg, Pavel Pihera, Miroslav Havranek
-
Patent number: 7125442Abstract: A lightfast additive and an ink composition including the same include a benzophenone moiety for lightfastness and a moiety for wettability and the ability to stabilize a colorant, wherein the two moieties are covalently bonded. The lightfast additive may exhibit effective ultraviolet (UV) light absorption capacity, effective wettability, and an ability to stabilize a colorant. The ink composition utilizing the light fast additive thus has an improved lightfastness and long-term storage stability.Type: GrantFiled: May 24, 2004Date of Patent: October 24, 2006Assignee: Samsung Electronics Co., Ltd.Inventors: Kyung-hoon Lee, Seung-min Ryu, Yeon-kyoung Jung
-
Patent number: 7091237Abstract: A compound of formula (I) or pharmaceutically acceptable salts and solvates thereof, for the treatment of a hPPAR mediated disease or conditionType: GrantFiled: May 9, 2002Date of Patent: August 15, 2006Assignee: SmithKline Beecham CorporationInventors: Paul John Beswick, Christopher Charles Hamlett, Vipulkumar Patel, Michael Lawrence Sierra, Nigel Grahame Ramsden
-
Patent number: 7037914Abstract: A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.Type: GrantFiled: September 23, 2002Date of Patent: May 2, 2006Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Hisao Tajima, Yoshisuke Nakayama, Daikichi Fukushima
-
Patent number: 7022726Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an ? bonds, the solid triangle represents a ? bond, the wavy segments represent ? or ? bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3 is heteroaryl or a substituted heteroaryl radical, R1 and R2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) and wherein R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.Type: GrantFiled: November 4, 2003Date of Patent: April 4, 2006Assignee: Allergan, Inc.Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
-
Patent number: 6921822Abstract: The present invention relates to a process for preparing stereoisomerically enriched 4-aryl-4-hydroxybutanoic acid derivatives by reducing 4-aryl-4-ketobutanoic acid derivatives in the presence of ruthenium-containing catalysts.Type: GrantFiled: June 9, 2003Date of Patent: July 26, 2005Assignee: Bayer AktiengesellschaftInventors: Hans-Christian Militzer, Boris Bosch, Markus Eckert, Benjamin Meseguer
-
Patent number: 6825360Abstract: The invention relates to novel bicyclic aromatic compounds which have the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.Type: GrantFiled: July 19, 2000Date of Patent: November 30, 2004Assignee: Galderma Research & Development S.N.C.Inventor: Jean-Michel Bernardon
-
Publication number: 20040204594Abstract: This invention relates to preparation of enantio-enriched compounds, and more particularly to enantio-enriched kavalactone compounds and derivatives thereof. The methods provide compounds that are useful as reagents, or building blocks, in the construction of other enantio-enriched compounds.Type: ApplicationFiled: January 12, 2004Publication date: October 14, 2004Inventors: Shoujun Chen, Lijun Sun, Joel McCleary
-
Publication number: 20040192908Abstract: The invention concerns novel molecules, their preparation and their uses, in particular in the field of human and veterinary medicine and cosmetics. The inventive compounds are partly fatty acid derivatives and exhibit advantageous pharmacological and cosmetic properties. The invention also concerns various uses of said compounds, the pharmaceutical compositions containing them and methods for preparing them.Type: ApplicationFiled: January 21, 2004Publication date: September 30, 2004Inventors: Jamila Najib-Fruchart, Karine Caumont-Bertrand